Crispr Therapeutics AG (CRSP) stock has risen 38.14% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 62 out of a possible 100.
That rank is mainly influenced by a short-term technical score of 79. CRSP's rank also includes a long-term technical score of 76. The fundamental score for CRSP is 31. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 71.222. This means analysts expect the stock to increase 33.67% over the next 12 months.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock has risen 1.68% while the S&P 500 has risen 0.41% as of 1:42 PM on Thursday, Apr 23. CRSP has risen $0.88 from the previous closing price of $52.40 on volume of 260,964 shares. Over the past year the S&P 500 is down -3.98% while CRSP has risen 38.14%. CRSP earned $1.17 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 45.37.